# A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

> **NCT00614471** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 219 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Entecavir
- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** peginterferon alfa-2a [Pegasys]

## Key facts

- **NCT ID:** NCT00614471
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00614471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00614471, "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00614471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*